Legal status | |
---|---|
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C32H38N4O6S |
Molar mass | 606.74 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
TMC-647055 is an experimental antiviral drug which was developed as a treatment for hepatitis C, and is in clinical trials as a combination treatment with ribavirin and simeprevir. It acts as a NS5b polymerase inhibitor.
References
- Vendeville S, Lin TI, Hu L, Tahri A, McGowan D, Cummings MD, et al. (July 2012). "Finger loop inhibitors of the HCV NS5b polymerase. Part II. Optimization of tetracyclic indole-based macrocycle leading to the discovery of TMC647055". Bioorganic & Medicinal Chemistry Letters. 22 (13): 4437–43. doi:10.1016/j.bmcl.2012.04.113. PMID 22633687.
- Cummings MD, Lin TI, Hu L, Tahri A, McGowan D, Amssoms K, et al. (March 2014). "Discovery and early development of TMC647055, a non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase". Journal of Medicinal Chemistry. 57 (5): 1880–92. doi:10.1021/jm401396p. PMID 24144360.
- Bourgeois S, Van Vlierberghe H, Moreno C, Orlent H, Nevens F, Arastéh K, et al. (February 2017). "Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection". BMC Gastroenterology. 17 (1): 26. doi:10.1186/s12876-017-0580-2. PMC 5303260. PMID 28187751.
RNA virus antivirals (primarily J05, also S01AD and D06BB) | |||||||||
---|---|---|---|---|---|---|---|---|---|
Hepatitis C |
| ||||||||
Hepatitis D | |||||||||
Picornavirus | |||||||||
Anti-influenza agents | |||||||||
Multiple/general |
| ||||||||
|
This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it. |